Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

MBX Biosciences (MBX) Accumulated Depreciation & Amortization (2023 - 2026)

MBX Biosciences has reported Accumulated Depreciation & Amortization over the past 4 years, most recently at $734000.0 for Q1 2026.

  • Quarterly results put Accumulated Depreciation & Amortization at $734000.0 for Q1 2026, up 47.09% from a year ago — trailing twelve months through Mar 2026 was $734000.0 (up 47.09% YoY), and the annual figure for FY2025 was $670000.0, up 58.77%.
  • Accumulated Depreciation & Amortization reached $734000.0 in Q1 2026 per MBX's latest filing, up from $670000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $734000.0 in Q1 2026 and bottomed at $178000.0 in Q4 2023.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $529500.0 (2025), compared with a mean of $504625.0.
  • The largest annual shift saw Accumulated Depreciation & Amortization surged 137.08% in 2024 before it surged 47.09% in 2026.
  • Over 4 years, Accumulated Depreciation & Amortization stood at $178000.0 in 2023, then soared by 137.08% to $422000.0 in 2024, then soared by 58.77% to $670000.0 in 2025, then grew by 9.55% to $734000.0 in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for MBX at $734000.0 in Q1 2026, $670000.0 in Q4 2025, and $610000.0 in Q3 2025.